Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
Report
Real-time Quote. Real-time Tradegate - 10/24 11:32:55 am
61.49 EUR   0.00%
10/20 UCB FIRST NINE :  Strong 9 …
10/20 UCB : By the time you finish reading this headline another person &h..
10/17UCB SA : quaterly earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies

Jordan Dufee

 
 
share with twitter share with LinkedIn share with facebook
share via e-mail

After the accumulation, an upward acceleration ?

Strategy published on 10/06/2017 | 09:34
long trade
Live
Entry price : 60.47€ | Target : 66€ | Stop-loss : 58€ | Potential : 9.15%
From a horizontal accumulation phase, the timing seems good to buy shares in UCB and to get ahead of a break-out on the upside of the congestion area.
Investors have an opportunity to buy the stock and target the € 66.
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 56.5, which offers good timing for buyers.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Weaknesses
  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
UCB0.95%14 058
JOHNSON & JOHNSON23.60%385 476
NOVARTIS13.97%226 424
PFIZER12.13%216 767
ROCHE HOLDING LTD.0.77%206 094
MERCK AND COMPANY7.69%172 914
AMGEN23.47%131 728
SANOFI9.74%125 259
BAYER18.28%113 967
BRISTOL-MYERS SQUIBB COMPAN..10.23%104 545
NOVO NORDISK A/S25.13%98 961
GLAXOSMITHKLINE-2.72%98 757
ABBOTT LABORATORIES46.00%97 436
ELI LILLY AND COMPANY18.53%95 984
CELGENE CORPORATION5.72%95 736
ASTRAZENECA15.83%85 811
More Results
Financials (€)
Sales 2017 4 345 M
EBIT 2017 983 M
Net income 2017 625 M
Debt 2017 595 M
Yield 2017 1,95%
P/E ratio 2017 17,79
P/E ratio 2018 15,47
EV / Sales 2017 2,89x
EV / Sales 2018 2,66x
Capitalization 11 960 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart UCB
Duration : Period : Day
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Duration : Period : Week
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders